Angion Biomedica’s bid to treat delayed graft function (DGF) following kidney transplantation is strong with clinical signals and mechanistic potential.
The FDA Likelihood of Approval (LoA) for Amgen’s Nplate (romiplostim) in aplastic anaemia jumped 11...
Deciding when to deploy boosters for Moderna’s and Pfizer/BioNTech’s Covid-19 messenger RNA (mRNA) vaccines will not rely on a single...
Keros Therapeutics’ KER-050 to treat anaemia in myelodysplastic syndrome (MDS) patients needs 30% of Phase II part 2 trial participants...
Bharat Biotech is reviewing interim safety and immunogenicity data from a Phase I trial investigating its intranasal Covid-19 vaccine BBV154,...
Ortho Dermatologics’ IDP-126 in moderate-to-severe acne vulgaris saw a 12-point upswing in its Likelihood of Approval (LoA) after positive topline results were reported from a second Phase III trial. Topical…
As of 26 April, the likelihood of approval (LoA) score for the RSV antibody respiratory syncytial virus (RSV) drug nirsevimab that is being developed by AstraZeneca and Sanofi climbed up…
Guangzhou Link Health Pharma and George Clinical have signed a term sheet to enter a strategic agreement to launch a clinical development company to deliver trials. The new independent joint…
Idera Pharmaceuticals has revealed that the Phase III, pivotal ILLUMINATE-301 trial of tilsotolimod in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) versus Yervoy alone in patients with anti-programmed death protein-1…
High mortality and poor existing options result in widespread uptake Soliris price point and some payer pushback make replacement ideal Experts confident in approval given rare indication and Phase II…
The likelihood of approval (LoA) for Pfizer’s binimetinib in acute myeloid leukaemia (AML) plummeted 17 points on 21 April, according to GlobalData’s LoA data. The fall was triggered after the…
© Copyright Verdict Media Limited 2021
